The post hoc analysis found that tirzepatide at all doses investigated reduced the prevalence of metabolic syndrome related to cardiovascular risk factors more than placebo, semaglutide 1 mg, insulin degludec, and insulin glargine [117]. The gene discussed is INS; the disease is metabolic syndrome.